Abstract: Embossed tissue products having improved strength and softness are disclosed. The products as described have a continuous curvilinear emboss element which carries discrete emboss elements, thereby providing the product with the softness and handfeel benefits associated with the long linear elements, but the visual appearance of discrete emboss elements.

Abstract: Embossed tissue products having improved strength and softness are disclosed. The products as described have a continuous curvilinear emboss element which carries discrete emboss elements, thereby providing the product with the softness and handfeel benefits associated with the long linear elements, but the visual appearance of discrete emboss elements.

Abstract: Multi-ply paper products and methods of making such products includes providing a first furnish including a primary pulp having papermaking fibers with a weight-weighted average fiber length, a coarseness of about sixteen milligrams per one hundred meters or lower, and being at least eighty percent of the papermaking fibers of the first furnish, forming a nascent web having at least two layers, one of the layers being a surface layer of the nascent web and formed from the first furnish, dewatering the nascent web to form a dewatered web, and drying the dewatered web to form a multi-ply paper product. The multi-ply paper product includes a first ply and a second ply arranged such that an inner layer of the first ply is adjacent to an inner layer of the second ply and the inner layer of the first ply is attached to the inner layer of the second ply.

Abstract: Embossed tissue products having improved strength and softness are disclosed. The products as described have a continuous curvilinear emboss element which carries discrete emboss elements, thereby providing the product with the softness and handfeel benefits associated with the long linear elements, but the visual appearance of discrete emboss elements.

Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

Abstract: Methods are provided for inhibiting or treating stenosis or restenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective amount of a therapeutic agent via a catheter. Also provided is a catheter adapted for administering a therapeutically effective amount of a therapeutic agent to a mammalian host for inhibiting or treating stenosis or restenosis.

Abstract: Methods, devices and systems for compressing images are provided. One method includes creating halftone mask structures and applying compression coding techniques to arrayed pixels sorted using the halftone mask structures in order to convert an image to a compressed multi-level, halftoned image.

Abstract: A system and method for automatically creating a digital test materials to qualify and test forms processing systems, including preparing a handprint snippet database containing labeled handprint image snippets representing a unique human hand, preparing a form description file and a data content file, selecting handprint snippets from the handprint snippet data base to formulate a form using the data content file, creating a form image using the selected snippets according to the form description file, and, if desired, printing the form image.

Abstract: Methods, devices and systems for compressing images are provided. One method includes creating halftone mask structures and applying compression coding techniques to arrayed pixels sorted using the halftone mask structures in order to convert an image to a compressed bi-level, halftoned image.

Abstract: Methods, devices and systems for compressing images are provided. One method includes creating halftone mask structures and applying compression coding techniques to arrayed pixels sorted using the halftone mask structures in order to convert an image to a compressed multi-level, halftoned image.

Abstract: Methods, devices and systems for compressing images are provided. One method includes creating halftone mask structures and applying compression coding techniques to arrayed pixels sorted using the halftone mask structures in order to convert an image to a compressed bi-level, halftoned image.

Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

Abstract: A half-tone mask is characterized by an N.times.M array of mask value locations associated with at least a portion of the pixels of the digital image. The size of the mask array may contain a relatively small number of pixel locations, which is applied spatially to mutually contiguous subsets or sub-arrays of pixels of a relatively high resolution digital image. Although the mask may also be made large enough to encompass the entire image of interest, respective threshold values of the mask may be computed `on the fly`, so as to obviate the need to prestore all of the threshold values of the mask. Each of the locations of the mask array is assigned a respectively different grey scale/half-tone conversion threshold value. These threshold values are distributed among the locations of the mask array such that as one proceeds through the mask array, the next sequential location is specified in accordance with fractional parts of integral multiples of a two-dimensional analog of the Golden Mean.